A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

What Was Tested

In this phase 2 trial, researchers set out to test Retatrutide.

This is a study of LY3437943 in participants who have obesity or are overweight.

The main purpose is to learn more about how LY3437943 affects body weight loss.

The study will last about 18 months and may include up to 18 visits.

Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).

The registry classes the interventions as drug.

Who Took Part

The registry lists 338 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 2 inclusion and 15 exclusion criteria; among the exclusions: participants must not have type 1 or type 2 diabetes mellitus; participants must not have had surgery for obesity or plan to have such surgery during the study; participants must not be using medications that promote weight loss or cause weight gain.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Retatrutide and who got the comparison, which limits bias.

The Retatrutide group and the comparison group ran side by side rather than switching.

As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2021-05-20 with completion listed for 2022-05-16.

It ran at 28 sites in United States (25) and Puerto Rico (3).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Mean Percent Change From Baseline in Body Weight (time frame: Baseline, Week 24).

It also tracked 13 secondary outcomes, for example Mean Percent Change From Baseline in Body Weight, Mean Change From Baseline in Body Weight, Mean Change From Baseline in Body Weight, Mean Change From Baseline in BMI, Mean Change From Baseline in BMI and Mean Change From Baseline in Waist Circumference.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Retatrutide in 338 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Retatrutide compound page, all human trials.